Related Experiment Videos
Samarium-153 chelate localization in malignant melanoma
J H Turner1, A A Martindale, G C de Witt
1Department of Nuclear Medicine, Fremantle Hospital, Western Australia.
European Journal of Nuclear Medicine
|January 1, 1987
Summary
Samarium-153 (153Sm) chelates were evaluated for tumor localization and endoradiotherapy potential in melanoma models. 153Sm-HEDTA showed the best tumor delineation, indicating promise for targeted cancer treatment.
Area of Science:
- Nuclear Medicine
- Radiopharmaceutical Chemistry
- Oncology
Background:
- Samarium-153 (153Sm) is a radiolanthanide with suitable gamma and beta emissions for imaging and therapy.
- Various 153Sm chelates were synthesized to assess their potential for tumor targeting.
Purpose of the Study:
- To evaluate the tumor localization and endoradiotherapeutic potential of various 153Sm chelates in B16 murine melanoma models.
- To compare the biodistribution and imaging characteristics of different 153Sm chelates.
Main Methods:
- 153Sm was produced in a nuclear reactor.
- 153Sm chelates (DTPA, HEDTA, HIDA, BZ, PBH, PIH, NTA) were prepared and characterized chromatographically.
- Biodistribution studies were conducted in mice bearing B16 melanoma, with measurements at 1, 6, 24, and 48 hours post-injection.
- Histopathological examination confirmed tumor comparability.
Main Results:
- 153Sm-chloride and 153Sm-citrate showed rapid hepatic accumulation due to colloid formation.
- 153Sm-DTPA was rapidly excreted renally with no tumor uptake.
- Other 153Sm chelates localized in both melanotic and amelanotic tumors, but less than 67Ga-citrate.
- 153Sm-HIDA and 153Sm-NTA showed high liver and bone uptake, respectively, impairing tumor definition.
- 153Sm-HEDTA provided the best tumor delineation among the evaluated chelates.
Conclusions:
- 153Sm-HEDTA demonstrates favorable characteristics for imaging and potential therapeutic applications in melanoma.
- Chelation significantly influences the biodistribution and tumor targeting of 153Sm.
- Further development of 153Sm chelates is warranted for endoradiotherapy.